Coupling factor 6 enhances the spontaneous microaggregation of platelets by decreasing cytosolic cAMP irrespective of antiplatelet therapy

Hypertension Research

Volumn 36, Issue 6, 2013, Pages 520-527

  Sukekawa, Takanori ^a   Osanai, Tomohiro ^a   Nishizaki, Fumie ^a   Metoki, Norifumi ^b   Hagii, Joji ^b   Kamada, Takaatsu ^b   Yasujima, Minoru ^b   Tomita, Hirofumi ^a   Magota, Koji ^c   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Hirosaki Stroke and Rehabilitation Center ^*  (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

cyclic AMP; G protein; platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ADENYLATE CYCLASE ACTIVATOR; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CHOLERA TOXIN; CILOSTAZOL; CLOPIDOGREL; COUPLING FACTOR 6; CYCLIC AMP; FORSKOLIN; MEMBRANE PROTEIN; PERTUSSIS TOXIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SPONTANEOUS MICROAGGREGATION OF PLATELET; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG;

ACIDOSIS; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CELL MEMBRANE; CEREBROVASCULAR ACCIDENT; CONCENTRATION (PARAMETERS); COUPLING FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIGHT SCATTERING; MAJOR CLINICAL STUDY; MALE; PROTEIN BINDING; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

AGED; AREA UNDER CURVE; ATP SYNTHETASE COMPLEXES; BLOTTING, WESTERN; CHOLERA TOXIN; CYCLIC AMP; CYTOSOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; OXIDATIVE PHOSPHORYLATION COUPLING FACTORS; P-SELECTIN; PERTUSSIS TOXIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RADIOIMMUNOASSAY; RISK FACTORS; STIMULATION, CHEMICAL; STROKE; TETRAZOLES;

EID: 84878906986     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.231     Document Type: Article

References (39)

1. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181-2188.
2. Ferroni P, Basili S, Falco A, Dav? G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-1291. (Pubitemid 40186123)
3. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234. (Pubitemid 35373553)
4. Satoh K, Ozaki Y, Qi R, Yang L, Asazuma N, Yatomi Y, Kume S. Factors that affect the size of platelet aggregates in epinephrine-induced activation: a study using the particle counting method based upon light scattering. Thromb Res 1996; 81: 515-523. (Pubitemid 26101333)
5. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554. (Pubitemid 20176694)
6. Osanai T, Magota K, Tanaka M, Shimada M, Murakami R, Sasaki S, Tomita H, Maeda N, Okumura K. Intracellular signaling for vasoconstrictor coupling factor 6: novel function of b-subunit of ATP synthase as receptor. Hypertension 2005; 46: 1140-1146. (Pubitemid 41533017)
7. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R. Ectopic b-chain of ATP synthase is an apolopoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421: 75-79. (Pubitemid 36077087)
8. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999; 96: 2811-2816. (Pubitemid 29148800)
9. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, Cheek DJ, Pizzo SV. Endothelial cell surface F1-Fo ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98: 6656-6661. (Pubitemid 32538272)
10. Osanai T, Okada S, Sirato K, Nakano T, Saitoh M, Magota K, Okumura K. Mitochondrial coupling factor 6 is present on the surface of human vascular endothelial cells and released by shear stress. Circulation 2001; 104: 3132-3136. (Pubitemid 34014070)
11. Sasaki S, Osanai T, Tomita H, Matsunaga T, Magota K, Okumura K. Tumor necrosis factor a as an endogenous stimulator for circulating coupling factor 6. Cardiovasc Res 2004; 62: 578-586. (Pubitemid 38648972)
12. Osanai T, Kamada T, Fujiwara N, Katoh T, Takahashi K, Kimura M, Satoh K, Magota K, Kodama S, Tanaka T, Okumura K. A novel inhibitory effect on prostacyclin synthesis of coupling factor 6 extracted from the heart of spontaneously hypertensive rats. J Biol Chem 1998; 273: 31778-31783. (Pubitemid 29177110)
13. Tanaka M, Osanai T, Murakami R, Sasaki S, Tomita H, Maeda N, Satoh K, Magota K, Okumura K. Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: enhanced release of asymmetric dimethylarginine. J Hypertens 2006; 24: 489-497. (Pubitemid 43261913)
14. Kumagai A, Osanai T, Katoh C, Tanaka M, Tomita H, Morimoto T, Murakami R, Magota K, Okumura K. Coupling factor 6 downregulates platelet endothelial cell adhesion molecule-1 via c-Src activation and acts as a proatherogenic molecule. Atherosclerosis 2008; 200: 45-50.
15. Osanai T, Tanaka M, Kamada T, Nakano T, Takahashi K, Okada S, Sirato K, Magota K, Kodama S, Okumura K. Mitochondrial coupling factor 6 as a novel endogenous vasoconstrictor. J Clin Invest 2001; 108: 1023-1030. (Pubitemid 32946076)
16. Osanai T, Tomita H, Kushibiki M, Yamada M, Tanaka M, Ashitate T, Echizen T, Katoh C, Magota K, Okumura K. Coupling factor 6 enhances Src-mediated responsiveness to angiotensin II in resistance arterioles and cells. Cardiovasc Res 2009; 81: 780-787.
17. Osanai T, Sasaki S, Kamada T, Fujiwara N, Nakano T, Tomita H, Matsunaga T, Magota K, Okumura K. Circulating coupling factor 6 in human hypertension: role of reactive oxygen species. J Hypertens 2003; 21: 2323-2328. (Pubitemid 38293572)
18. Ashitate T, Osanai T, Tanaka M, Magota K, Echizen T, Izumiyama K, Yokoyama H, Shibutani S, Hanada K, Tomita H, Okumura K. Overexpression of coupling factor 6 causes cardiac dysfunction under high salt diet in mice. J Hypertens 2010; 28: 2243-2251.
19. Izumiyama K, Osanai T, Sagara S, Yamamoto Y, Itoh T, Sukekawa T, Nishizaki F, Magota K, Okumura K. Estrogen attenuates coupling factor 6-induced salt-sensitive hypertension and cardiac systolic dysfunction in mice. Hypertens Res 2012; 35: 539-546.
20. Osanai T, Tanaka M, Magota K, Tomita H, Okumura K. Coupling factor 6-induced activation of ecto-F1Fo complex induces insulin resistance, mild glucose intolerance and elevated blood pressure in mice. Diabetologia 2012; 55: 520-529.
21. Sagara S, Osanai T, Itoh T, Izumiyama K, Shibutani S, Hanada K, Yokoyama H, Yamamoto Y, Yokota T, Tomita H, Magota K, Okumura K. Overexpression of coupling factor 6 attenuates exercise-induced physiological cardiac hypertrophy by inhibiting PI3K/Akt signaling in mice. J Hypertens 2012; 30: 778-786.
22. Boyer PD. The binding change mechanism for ATP synthase: some probabilities and possibilities. Biochim Biophys Acta 1993; 1140: 215-250. (Pubitemid 23015689)
23. Walker JE, Fearnley IM, Gay NJ, Gibson BW, Northrop FD, Powell SJ, Runswick MJ, Saraste M, Tybulewicz VL. Primary structure and subunit stoichiometry of F1-ATPase from bovine mitochondria. J Mol Biol 1985; 184: 677-701. (Pubitemid 15024774)
24. Araki S, Matsuno H, Haneda M, Kyoya D, Kanno Y, Itho J, Kishi A, Isshiki K, Sugimoto T, Maegawa H, Kashiwagi A, Uzu T. Correlation between albuminuria and spontaneous platelet microaggregate formation in type 2 diabetic patients. Diabetes Care 2009; 32: 2062-2067.
25. Di Minno G, Violi F. Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res 2004; 113: 97-99. (Pubitemid 38534486)
26. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
27. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004; 148: 263-268. (Pubitemid 39092790)
28. Charo IF, Feinman RD, Detwiler TC. Interrelations of platelet aggregation and secretion. J Clin Invest 1977; 60: 866-873. (Pubitemid 8208479)
29. Coller BS. Platelet and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
30. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation I: evidence for three distinct ADP receptors on platelets. J Biol Chem 1998; 273: 2024-2029. (Pubitemid 28069248)
31. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-1598. (Pubitemid 32574645)
32. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934.
33. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153-1161. (Pubitemid 33055619)
34. Manns JM, Brenna KJ, Colman RW, Sheth SB. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases. Thromb Haemost 2002; 87: 873-879. (Pubitemid 34516617)
35. Osanai T, Nakamura M, Sasaki S, Tomita H, Saitoh M, Osawa H, Yamabe H, Murakami S, Magota K, Okumura K. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease. Kidney Int 2003; 64: 2291-2297. (Pubitemid 37449566)
36. Osanai T, Fujiwara N, Sasaki S, Metoki N, Saitoh G, Tomita H, Nishimura T, Shibitani S, Yokoyama H, Konta Y, Magota K, Okumura K. Novel pro-atherogenic molecule coupling factor 6 is elevated in patients with stroke: a possible linkage to homocysteine. Ann Med 2010; 42: 79-86.
37. Ding WH, Chu SY, Jiang HF, Cai DY, Pang YZ, Tang CS, Qi YF. Plasma mitochondrial coupling factor 6 in patients with acute myocardial infarction. Hypertens Res 2004; 27: 717-722. (Pubitemid 40045510)
38. Li XL, Xing QC, Gao YY, Dong B, Pang YZ, Jiang HF, Tang CS. Plasma level of mitochondrial coupling factor 6 increases in patients with type 2 diabetes mellitus. Int J Cardiol 2007; 117: 411-412. (Pubitemid 46507638)
39. Tomita H, Osanai T, Toki T, Sasaki S, Maeda N, Murakami R, Magota K, Yasujima M, Okumura K. Troglitazone and 15-deoxy-deta 12, 14-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells. Cardiovasc Res 2005; 67: 134-141. (Pubitemid 40798300)